SCHEDULE 13G/A: Deep Track Capital and Affiliates Maintain 4.14% Passive Stake in Onkure Therapeutics

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly reported a 4.14% passive beneficial ownership stake in Onkure Therapeutics, Inc. as of December 31, 2024.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively hold a beneficial ownership of 523,989 shares of Onkure Therapeutics, Inc. Common Stock.
• This ownership represents 4.14% of the total class of securities outstanding.
• The calculation of the percentage of class is based on 12,652,890 Common Stock shares outstanding as of November 4, 2024, as reported by Onkure Therapeutics, Inc. in its 10-Q filing.
• The reporting persons have shared voting power and shared dispositive power over all 523,989 shares.
• The filing is an Amendment No. 2 to Schedule 13G, indicating a passive investment purpose and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a standard beneficial ownership disclosure (Schedule 13G) and does not contain performance metrics, forward-looking statements, or operational updates that would typically influence sentiment. It merely reports a passive ownership stake, which is neutral in itself but the continued holding by an institutional investor can be seen as a minor positive signal.

Positives

• The continued holding of a passive stake by institutional investors like Deep Track Capital may signal a degree of confidence in Onkure Therapeutics, Inc.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of passive beneficial ownership by an institutional investor in a publicly traded company. It does not provide broader industry trends or specific insights into the biotechnology sector beyond the ownership stake in Onkure Therapeutics, Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership structure and the passive stake held by a notable institutional investor.

Key Dates

Keywords

Onkure Therapeutics, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, beneficial ownership, passive investment, common stock, institutional investor, SEC filing